The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved..
ETHNOPHARMACOLOGICAL RELEVANCE: Aidi injection (ADI) is a popular anti-tumor Chinese patent medicine, widely used in clinics for the treatment of hepatocellular carcinoma (HCC) with remarkable therapeutic effects through multiple targets and pathways. However, the scientific evidence of the synergistic role of the complex chemical component system and the potential mechanism for treating diseases are ignored and remain to be elucidated.
AIM OF THE STUDY: This study aimed to elucidate and verify the cooperative association between the potential active ingredient of ADI, which is of significance to enlarge our understanding of its anti-HCC molecular mechanisms.
MATERIALS AND METHODS: Firstly, the anti-HCC effect of ADI was evaluated in various HCC cells and the zebrafish xenograft model. Subsequently, a variety of bioinformatic technologies, including network pharmacology, weighted gene co-expression network analysis (WGCNA), meta-analysis of gene expression profiles, and pathway enrichment analysis were performed to construct the competitive endogenous RNA (ceRNA) network of ADI intervention in HCC and to establish the relationship between the critical targets/pathways and the key corresponding components, which were involved in ADI against HCC in a synergistic way and were validated by molecular biology experiments.
RESULTS: ADI exerted remarkable anti-HCC in vitro cells and in vivo zebrafish model, especially that the Hep 3B2.1-7 cell showed substantial sensibility to ADI. The ceRNA network revealed that the EGFR/PI3K/AKT signaling pathway was identified as the promising pathway. Furthermore, the meta-analysis also demonstrated the critical role of BIRC5 and FEN1 as key targets. Finally, the synergistic effect of ADI was revealed by discovering the inhibitory effect of cantharidin on BIRC5, formononetin on FEN1 and EGFR, as well as isofraxidin on EGFR.
CONCLUSION: Our study unveiled that the incredible protective effect of ADI on HCC resulted from the synergistic inhibition effect of cantharidin, formononetin, and isofraxidin on multiple targets/pathways, including BIRC5, FEN1, and EGFR/PI3K/AKT, respectively, providing a scientific interpretation of ADI against HCC and a typical example of pharmacodynamic evaluation of other proprietary Chinese patent medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:319 |
|---|---|
| Enthalten in: |
Journal of ethnopharmacology - 319(2023), Pt 2 vom: 30. Jan., Seite 117209 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Shan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.11.2023 Date Revised 20.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jep.2023.117209 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362542775 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362542775 | ||
| 003 | DE-627 | ||
| 005 | 20231226091446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jep.2023.117209 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362542775 | ||
| 035 | |a (NLM)37757991 | ||
| 035 | |a (PII)S0378-8741(23)01079-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Shan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.11.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a ETHNOPHARMACOLOGICAL RELEVANCE: Aidi injection (ADI) is a popular anti-tumor Chinese patent medicine, widely used in clinics for the treatment of hepatocellular carcinoma (HCC) with remarkable therapeutic effects through multiple targets and pathways. However, the scientific evidence of the synergistic role of the complex chemical component system and the potential mechanism for treating diseases are ignored and remain to be elucidated | ||
| 520 | |a AIM OF THE STUDY: This study aimed to elucidate and verify the cooperative association between the potential active ingredient of ADI, which is of significance to enlarge our understanding of its anti-HCC molecular mechanisms | ||
| 520 | |a MATERIALS AND METHODS: Firstly, the anti-HCC effect of ADI was evaluated in various HCC cells and the zebrafish xenograft model. Subsequently, a variety of bioinformatic technologies, including network pharmacology, weighted gene co-expression network analysis (WGCNA), meta-analysis of gene expression profiles, and pathway enrichment analysis were performed to construct the competitive endogenous RNA (ceRNA) network of ADI intervention in HCC and to establish the relationship between the critical targets/pathways and the key corresponding components, which were involved in ADI against HCC in a synergistic way and were validated by molecular biology experiments | ||
| 520 | |a RESULTS: ADI exerted remarkable anti-HCC in vitro cells and in vivo zebrafish model, especially that the Hep 3B2.1-7 cell showed substantial sensibility to ADI. The ceRNA network revealed that the EGFR/PI3K/AKT signaling pathway was identified as the promising pathway. Furthermore, the meta-analysis also demonstrated the critical role of BIRC5 and FEN1 as key targets. Finally, the synergistic effect of ADI was revealed by discovering the inhibitory effect of cantharidin on BIRC5, formononetin on FEN1 and EGFR, as well as isofraxidin on EGFR | ||
| 520 | |a CONCLUSION: Our study unveiled that the incredible protective effect of ADI on HCC resulted from the synergistic inhibition effect of cantharidin, formononetin, and isofraxidin on multiple targets/pathways, including BIRC5, FEN1, and EGFR/PI3K/AKT, respectively, providing a scientific interpretation of ADI against HCC and a typical example of pharmacodynamic evaluation of other proprietary Chinese patent medicine | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aidi injection | |
| 650 | 4 | |a BIRC5 | |
| 650 | 4 | |a FEN1 | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a PI3K-AKT signaling pathway | |
| 650 | 4 | |a Synergistic role | |
| 650 | 7 | |a formononetin |2 NLM | |
| 650 | 7 | |a 295DQC67BJ |2 NLM | |
| 650 | 7 | |a isofraxidin |2 NLM | |
| 650 | 7 | |a 304915F056 |2 NLM | |
| 650 | 7 | |a Cantharidin |2 NLM | |
| 650 | 7 | |a IGL471WQ8P |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Nonprescription Drugs |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a FEN1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.1.11.- |2 NLM | |
| 650 | 7 | |a Flap Endonucleases |2 NLM | |
| 650 | 7 | |a EC 3.1.- |2 NLM | |
| 650 | 7 | |a BIRC5 protein, human |2 NLM | |
| 650 | 7 | |a Survivin |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Huang, Jiaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zhihong |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a You, Leiming |e verfasserin |4 aut | |
| 700 | 1 | |a Stalin, Antony |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Meilin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhishan |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Libo |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Qiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Pengyun |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Chongjun |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jiarui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ethnopharmacology |d 1980 |g 319(2023), Pt 2 vom: 30. Jan., Seite 117209 |w (DE-627)NLM00095196X |x 1872-7573 |7 nnns |
| 773 | 1 | 8 | |g volume:319 |g year:2023 |g number:Pt 2 |g day:30 |g month:01 |g pages:117209 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jep.2023.117209 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 319 |j 2023 |e Pt 2 |b 30 |c 01 |h 117209 | ||